# Semax Research: Mechanism, Neuroprotection, and the Key Studies > Semax research, summarized: how it works, the BDNF and NGF data, the cerebral-ischemia neuroprotection record, and the immune-gene transcriptional shift. Heavily cited. Neurotrophins, neuroprotection in ischemia, and an immune-dominated gene-expression shift — read against the studies that measured them. ## Before the details Here is the Semax research in plain terms. Semax is a seven-amino-acid peptide that, in animal brains, quickly turns up the production of two natural "growth factors" — BDNF and NGF — that help nerve cells survive, grow, and form connections [1][2]. In stroke experiments, where part of the brain loses blood flow, Semax shrinks the damaged zone and calms the harmful inflammation that follows [4][5]. It also blocks an enzyme that normally breaks down the body's own pain- and mood-related opioid molecules, which may stretch out their signaling [3]. The catch: almost all of this is in rats and mice, the intact peptide disappears from the brain within minutes [6], and the longer effects are credited to a breakdown product called Pro-Gly-Pro [8]. The mechanism is real and reproducible — it is just mostly preclinical. ## How does semax work Semax does not act through one clean receptor switch. Its effects come from several overlapping actions. First, it rapidly and region-specifically raises the neurotrophins BDNF and NGF. A single 50 microg/kg intranasal dose raised NGF and BDNF messenger RNA in the rat hippocampus and BDNF in the brainstem and cerebellum, while NGF messenger RNA fell in the frontal cortex — a gene-specific, region-specific pattern rather than a uniform boost [2]. At 50 and 250 microg/kg it increased BDNF protein in the basal forebrain three hours after dosing and bound a specific, reversible, calcium-dependent site there with a dissociation constant of 2.4 nM [1]. Second, it inhibits enkephalin-degrading enzymes — the enzymes (notably neprilysin-type) that break down enkephalins, the body's own opioid peptides. In human serum in vitro, Semax did this with a half-maximal inhibitory concentration (IC50) of about 10 microM, more potently than puromycin and other reference inhibitors [3]. Prolonging endogenous opioid signaling is one plausible route to its mood and stress effects. Third, in stroke models its protection is dominated by an immunomodulatory and pro-vascular shift in brain gene expression rather than a single receptor action — covered in the neuroprotection section below. ## What does semax peptide do In measured terms, Semax does four things across the literature. It raises brain growth factors (BDNF and NGF) [1][2]. It protects brain tissue in cerebral ischemia, reducing infarct volume and preserving memory in rats [4]. It tunes monoamine systems — in mice, 0.15 mg/kg raised the serotonin metabolite 5-HIAA and potentiated amphetamine-evoked dopamine release without raising baseline dopamine on its own [20]. And it corrects behavioral deficits in stress models, having been used to reverse long-lasting negative effects of neonatal isolation in rats [15]. The metabolite Pro-Gly-Pro carries independent neurotrophic activity: both Semax and Pro-Gly-Pro activated transcription of neurotrophins and their receptor genes after cerebral ischemia [8]. ## Neuroprotection in cerebral ischemia This is the deepest and most reproduced part of the record — the neuroprotection-in-ischemia angle. Intranasal Semax given for six days in a rat model of focal photoinduced prefrontal-cortex ischemia decreased the volume of cortical infarction and improved retention of a conditioned passive-avoidance response, an antiamnesic (memory-preserving) effect [4]. The mechanism behind that protection is now mapped at several molecular levels. Genome-wide transcriptional analysis after permanent middle-cerebral-artery occlusion in rats showed Semax predominantly modulated immune-system genes — immunoglobulins and chemokines made up over 50% of the affected genes — and altered vascular-system genes (24 genes at 3 hours, 12 at 24 hours), framing immunomodulation and vascular regulation as the key mechanisms of its neuroprotection [5]. Independent transcriptome and proteome studies after ischemia-reperfusion confirmed the protective program at both the RNA and protein levels [9][10], and Semax suppressed messenger RNA transcripts encoding pro-inflammatory mediators after reversible cerebral ischemia [11]. Synthetic ACTH peptides including Semax also modulated immune-gene expression in the early post-stroke window [12], and Semax — but not glycine — prevented the enhanced nitric-oxide generation in the cortex of rats with incomplete global ischemia [14]. A 2025 study extended the picture beyond stroke: in mice with spinal-cord injury, Semax improved functional recovery and reduced a form of inflammatory cell death (pyroptosis), acting on the mu-opioid-receptor gene Oprm1 through a USP18 and FTO deubiquitination pathway [7]. ## N-Acetyl Semax Amidate N-Acetyl Semax Amidate is a modified analog with an acetyl group added to the N-terminus and an amide group on the C-terminus, both intended to slow enzymatic breakdown relative to unmodified Semax. It is a frequent subject of research-community discussion, and some users single it out for verbal fluency. The rationale is the same one that motivated the original Pro-Gly-Pro tail: the unmodified peptide is cleared fast, and the stability of Semax acetate to proteolysis in biological media has been characterized directly [16]. The independent published pharmacology of the acetylated-amidated analog specifically remains thin compared with the parent peptide, so claims that distinguish it from Semax are largely community reports rather than trial data. ## How the human evidence reads Human data are limited and mostly Eastern European. One of the first human investigations documented Semax-associated changes on the electroencephalogram [17]; a clinical study reported a therapeutic effect in optic-nerve disease, a registered Russian indication [18]; and a resting-state functional-connectivity study examined the effects of Selank and Semax, one of the few modern human-imaging investigations [19]. There are no published Western randomized controlled trials and no controlled human trials specifically for ADHD, Parkinson's, or Alzheimer's disease — the neurodegeneration evidence is preclinical. That gap is the single most important caveat on every claim above. --- Filed from the published record on Semax like a front-page dispatch — the rodent neuroprotection and BDNF findings set in plain ink, the Russia-and-Ukraine-only registration and the missing Western trials printed in the same column, with no clinic behind the masthead and nothing here dosed, sourced, or sold.